KETJU Research

← The Register

Other

Gains Network

Not approved Too small to exit at size
Issued
2026-08-15
Last confirmed
2026-08-15
Next check due
2026-11-15
Chains
Arbitrum One · Mixed control, Base · Mixed control, Polygon PoS · Mixed control

Gains Network builds decentralized trading products and is best known for its gTrade perpetuals platform, where depositor vaults take the other side of trader profit and loss. It held $10.2 million across Arbitrum, Base, Polygon, MegaETH, and ApeChain at the 2026-08-15 survey. The registry rejects it because of its size. One practice advising 100 households moves $1M to $8M into a venue based on the same research. Below the size floor, that book can overwhelm the exit. The individual review does not open until the protocol clears the floor. Size alone decides the judgment, whatever the protocol’s quality. At size, the review would need to address vaults whose returns depend on traders losing.

The research file

Product and class applicability

Gains documents its ERC-4626 gToken collateral vaults as the counterparty to gTrade positions. Trader losses enter the vault, trader wins are paid from it, and trading fees accrue to it. That derivatives-counterparty process requires a full review at scale. At the current size, no more specific shared dossier replaces the v1 below-materiality rule.

Current observation and perimeter

The DefiLlama API read on 2026-08-15 reported approximately $10.2M across Arbitrum, Base, Polygon, MegaETH and ApeChain and classified Gains as derivatives. ApeChain is added to the registry review. The independently tracked aggregate remains far below the size floor, so the individual review does not open.

Control, loss and exit applicability

Vault share price includes fees and open trader PnL, so depositors can lose principal when traders win. Gains describes epoch-based withdrawal requests with locks of one, two, or three epochs, depending on collateralization. A missed withdrawal window requires a new request. Exit therefore depends on the collateral ratio, oracle-updated PnL, epoch processing, and available vault assets.

Why the class rule decides

The shared v1 below-materiality dossier decides the result at approximately $10.2M and does not approve the counterparty design. The individual review does not open until TVL is independently reproducible above the size floor for 30 days. Then review each collateral vault’s trader exposure, collateral ratio, oracle and governance authority, caps, fees, audits, incidents, chain dependencies, withdrawal epochs, and losses under one-sided profitable-trader stress.

Research status

This is a capacity-unproven record for Gains Network, not a quality rejection or approval. Reported TVL says how big the venue is, not what the client owns, who can change the rules, or how a position exits at a proposed size. The individual review opens when the protocol clears the size floor.

Sources

The claims above trace to these. Where a number could not be independently verified, the thesis says so.

Inherited controls

The research above describes the protocol layer. Every position also inherits the asset it holds and the chain it settles on. The layer with the most administrative power sets the position’s effective control; that describes control, not quality or suitability.

ChainVerdictControlControl constraint
Arbitrum OneApproved with limits Mixed control a single sequencer orders >99% of transactions and admin keys can upgrade bridge contracts on a ~7-day timelock.
BaseApproved with limits Mixed control Coinbase, one regulated US company, operates the only sequencer, and admin keys can upgrade bridge contracts within ~7 days.
Polygon PoSRejected Mixed control a public validator set orders transactions, but a 5-of-9 multisig can instantly upgrade staking and canonical bridge contracts, while a 5-of-8 controls custom child tokens.
The memo is public. Monitoring connects the research to positions clients actually hold and flags evidence changes for advisor review. $49 per advisor per month, first 14 days free. Start the trial.